Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Doxorubicin × NET × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 284 Breast 177 Other hematologic neoplasm 94 Sarcoma 84 Gastrointestinal 45 Genitourinary 35 Gynecologic 26 Plasma cell 25 CNS 19 Other solid neoplasm 13 Thoracic 10 Head & Neck 7 Endocrine 7 Myeloid 5 Dermatologic 5 Tumor-Agnostic 2 Classical hematology 2 Other 1 NET 1

Conditions

Neuroendocrine Tumors 1 Neoplasms 1 Neoplasm Metastasis 1

Interventions

lutetium Lu 177 dotatate 29 Everolimus 17 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 10 Temozolomide 9 Nivolumab 9 Capecitabine 9 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 lanreotide 7 Positron Emission Tomography Computed Tomography 7 Somatostatin 6 Octreotide 6 90Y-octreotide, DOTA-Tyr(3)- 6 pembrolizumab 5 cabozantinib 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 3-Iodobenzylguanidine 5 pasireotide 4 avelumab 4 Ipilimumab 4 Ga(III)-DOTATOC 4 Carboplatin 4 Al18F-NOTA-octreotide 4 telotristat ethyl 3 surufatinib 3 fluorodopa F 18 3 copper dotatate CU-64 3 Surveys and Questionnaires 3 Single Photon Emission Computed Tomography Computed Tomography 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01678664 2024-09-25

EVACEL

Federation Francophone de Cancerologie Digestive

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡